Table of Content

1. Key Insights

2. Executive Summary of ALK-NSCLC

3. SWOT Analysis of ALK-NSCLC

4. ALK-NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country

5. ALK-Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC

6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total ALK NSCLC cases in the United States
7.4.5. Total ALK NSCLC Treated patient Pool in the United States

8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total ALK NSCLC cases in Germany
8.1.5. Total ALK NSCLC Treated patient Pool in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total ALK NSCLC cases in France
8.2.5. Total ALK NSCLC Treated patient Pool in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total ALK NSCLC cases in Italy
8.3.5. Total ALK NSCLC Treated patient Pool in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total ALK NSCLC cases in Spain
8.4.5. Total ALK NSCLC Treated patient Pool in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total ALK NSCLC cases in the United Kingdom
8.5.5. Total ALK NSCLC Treated patient Pool in the United Kingdom

9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total ALK NSCLC cases in Japan
9.1.5. Total ALK NSCLC Treated patient Pool in Japan

10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of ALK NSCLC

13. Key Endpoints in ALK NSCLC Clinical Trials

14. Marketed Therapies
14.1. Key Cross
14.2. Alunbrig (Brigatinib): Takeda Pharmaceuticals
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Pivotal Clinical Trials
14.2.4. Ongoing Current Pipeline Activity
14.2.5. Safety and Efficacy of Ongoing Clinical Trials
14.3. Alecensa (Alectinib): Hoffmann-La Roche
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity

15. Emerging Therapies
15.1. X-396 (Ensartinib): Xcovery
15.1.1. Product Description
15.1.2. Clinical Development
15.1.3. Safety and Efficacy

16. ALK Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
16.1. Key Findings
16.2. Market Outlook: 7MM

17. ALK-Mutation?Market Size
17.1. Total Market Size of ALK NSCLC in the 7MM
17.2. Market Size of ALK NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of ALK NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of NSCLC in Japan

18. Market Access and Reimbursement of NSCLC Therapies

19. Market Drivers of ALK NSCLC

20. Market Barriers of ALK NSCLC
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight



List of Figures


Figure 1 NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total ALK NSCLC cases in the United States
Figure 22 Total ALK NSCLC Treated patient Pool in the United States
Figure 23 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 24 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 25 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 26 Total ALK NSCLC cases in Germany
Figure 27 Total ALK NSCLC Treated patient Pool in Germany
Figure 28 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 29 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 30 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 31 Total ALK NSCLC cases in France
Figure 32 Total ALK NSCLC Treated patient Pool in France
Figure 33 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 35 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 36 Total ALK NSCLC cases in Italy
Figure 37 Total ALK NSCLC Treated patient Pool in Italy
Figure 38 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 41 Total ALK NSCLC cases in Spain
Figure 42 Total ALK NSCLC Treated patient Pool in Spain
Figure 43 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 44 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 45 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 46 Total ALK NSCLC cases in the United Kingdom
Figure 47 Total ALK NSCLC Treated patient Pool in the United Kingdom
Figure 48 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 49 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 50 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 51 Total ALK NSCLC cases in Japan
Figure 52 Total ALK NSCLC Treated patient Pool in Japan
Figure 53 Advanced/Metastatic NSCLC Treatment Algorithm
Figure 54 Timeline Illustrating the Development of Targeted Therapies and Immunotherapies for the Treatment of NSCLC Over two decades
Figure 55 Immune Checkpoint Inhibitor
Figure 56 Unmet Needs
Figure 57 Market Size of ALK NSCLC in the 7MM, in USD Million (2017–2030)
Figure 58 Market Size of ALK NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 59 Market Size of ALK NSCLC by therapies by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 60 Market Size of ALK NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 61 Market Size of ALK NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 62 Market Size of ALK NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 63 Market Size of ALK NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 64 Market Size of ALK NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 65 Market Size of ALK NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 66 Market Size of ALK NSCLC in Japan by Therapies, in USD Millions (2017–2030)
Figure 67 Market Drivers
Figure 68 Market Barriers

 

List of Tables


Table 1 Summary of Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total ALK NSCLC cases in the United States
Table 10 Total ALK NSCLC Treated patient Pool in the United States
Table 11 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 12 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 13 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 14 Total ALK NSCLC cases in Germany
Table 15 Total ALK NSCLC Treated patient Pool in Germany
Table 16 Total Incident cases of NSCLC patients in France (2017–2030)
Table 17 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 18 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 19 Total ALK NSCLC cases in France
Table 20 Total ALK NSCLC Treated patient Pool in France
Table 21 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 23 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 24 Total ALK NSCLC cases in Italy
Table 25 Total ALK NSCLC Treated patient Pool in Italy
Table 26 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 29 Total ALK NSCLC cases in Spain
Table 30 Total ALK NSCLC Treated patient Pool in Spain
Table 31 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 32 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 33 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 34 Total ALK NSCLC cases in the United Kingdom
Table 35 Total ALK NSCLC Treated patient Pool in the United Kingdom
Table 36 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 37 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 38 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 39 Total ALK NSCLC cases in Japan
Table 40 Total ALK NSCLC Treated patient Pool in Japan
Table 41 Standard Treatment Options of NSCLC (Stage-wise)
Table 42 Summary of Recommendations (SEOM Clinical Guideline)
Table 43 Strength of Evidence
Table 44 Strength of Evidence
Table 45 Marketed Drugs Key Cross
Table 46 Lorbrena (Lorlatinib), Clinical Trial Description, 2020
Table 47 Alunbrig (Brigatinib), Clinical Trial Description, 2020
Table 48 Alecensa (Alectinib), Clinical Trial Description, 2020
Table 49 X-396 (Ensartinib), Clinical Trial Description, 2020
Table 50 7MM Market Size of ALK NSCLC, in USD Million (2017–2030)
Table 51 7MM Market Size of ALK NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 52 7MM Market Size of ALK NSCLC by therapies, in USD Million (2017–2030)
Table 53 United States Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 54 United States Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 55 Germany Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 56 Germany Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 57 France Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 58 France Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 59 Italy Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 60 Italy Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 61 Spain Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 62 Spain Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 63 United Kingdom Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 64 United Kingdom Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 65 Japan Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 66 Japan Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 67 National Institute for Health and Care Excellence (NICE) Decisions for NSCLC Therapies
Table 68 IQWiG Decisions for NSCLC Therapies
Table 69 Haute Autorit? de sant? (HAS) Decisions for NSCLC Therapies